Flumist shipment timing weighs on AZ revenues; DOD hands Profectus $9.5M for Ebola, Marburg trivalent;

> AstraZeneca's ($AZN) U.S. revenue grew 7% in Q3 despite a decline from the timing of FluMist shipments, it said Thursday. Release (PDF)

> Profectus BioSciences has locked down $9.5 million in Department of Defense funding to help it develop a trivalent vaccine for Ebola and Marburg. The cash will support manufacturing and preclinical testing for the vaccine, the company said. Release

> Vaccine-focused contract manufacturing organization Paragon Bioservices has closed a $13 million round of Series A financing. More

> A vaccine candidate that treats opioid abuse could help patients recover from drug addictions. Report

> In a Phase I trial, treatment with Genexine's immunotherapeutic HPV vaccine resulted in viral clearance and complete lesion regression in 7 of 9 treated patients with severe dysplasia or carcinoma in situ. Release

And Finally... A chlamydia vaccine could help save koalas from extinction. More

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.